• Je něco špatně v tomto záznamu ?

Multitargeting Prodrugs that Release Oxaliplatin, Doxorubicin and Gemcitabine are Potent Inhibitors of Tumor Growth and Effective Inducers of Immunogenic Cell Death

A. Sarkar, V. Novohradsky, M. Maji, T. Babu, L. Markova, H. Kostrhunova, J. Kasparkova, V. Gandin, V. Brabec, D. Gibson

. 2023 ; 62 (42) : e202310774. [pub] 20230912

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc24001045

A multitargeting prodrug (2) that releases gemcitabine, oxaliplatin, and doxorubicin in their active form in cancer cells is a potent cytotoxic agent with nM IC50s ; it is highly selective to cancer cells with mean selectivity indices to human (136) and murine (320) cancer cells. It effectively induces release of DAMPs (CALR, ATP & HMGB1) in CT26 cells facilitating more efficient phagocytosis by J774 macrophages than the FDA drugs or their co-administration. The viability of CT26 cells co-cultured with J774 macrophages and treated with 2 was reduced by 32 % compared to the non-treated cells, suggesting a synergistic antiproliferative effect between the chemical and immune reactions. 2 inhibited in vivo tumor growth in two murine models (LLC and CT26) better than the FDA drugs or their co-administration with significantly lower body weight loss. Mice inoculated with CT26 cells treated with 2 showed slightly better tumor free survival than doxorubicin.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24001045
003      
CZ-PrNML
005      
20240213093557.0
007      
ta
008      
240109s2023 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1002/anie.202310774 $2 doi
035    __
$a (PubMed)37646232
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Sarkar, Amrita $u Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, 9112102, Israel $1 https://orcid.org/0000000162476272
245    10
$a Multitargeting Prodrugs that Release Oxaliplatin, Doxorubicin and Gemcitabine are Potent Inhibitors of Tumor Growth and Effective Inducers of Immunogenic Cell Death / $c A. Sarkar, V. Novohradsky, M. Maji, T. Babu, L. Markova, H. Kostrhunova, J. Kasparkova, V. Gandin, V. Brabec, D. Gibson
520    9_
$a A multitargeting prodrug (2) that releases gemcitabine, oxaliplatin, and doxorubicin in their active form in cancer cells is a potent cytotoxic agent with nM IC50s ; it is highly selective to cancer cells with mean selectivity indices to human (136) and murine (320) cancer cells. It effectively induces release of DAMPs (CALR, ATP & HMGB1) in CT26 cells facilitating more efficient phagocytosis by J774 macrophages than the FDA drugs or their co-administration. The viability of CT26 cells co-cultured with J774 macrophages and treated with 2 was reduced by 32 % compared to the non-treated cells, suggesting a synergistic antiproliferative effect between the chemical and immune reactions. 2 inhibited in vivo tumor growth in two murine models (LLC and CT26) better than the FDA drugs or their co-administration with significantly lower body weight loss. Mice inoculated with CT26 cells treated with 2 showed slightly better tumor free survival than doxorubicin.
650    _2
$a myši $7 D051379
650    _2
$a lidé $7 D006801
650    _2
$a zvířata $7 D000818
650    _2
$a oxaliplatin $x farmakologie $7 D000077150
650    _2
$a gemcitabin $7 D000093542
650    12
$a prekurzory léčiv $x farmakologie $x terapeutické užití $7 D011355
650    _2
$a imunogenní buněčná smrt $7 D000079527
650    12
$a protinádorové látky $x farmakologie $x terapeutické užití $7 D000970
650    _2
$a doxorubicin $x farmakologie $x terapeutické užití $7 D004317
650    12
$a nádory $7 D009369
650    _2
$a nádorové buněčné linie $7 D045744
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Novohradsky, Vojtech $u Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, 61200, Brno, Czech Republic $1 https://orcid.org/0000000343818403
700    1_
$a Maji, Moumita $u Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, 9112102, Israel $1 https://orcid.org/0000000334400881
700    1_
$a Babu, Tomer $u Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, 9112102, Israel $1 https://orcid.org/0000000271063629
700    1_
$a Markova, Lenka $u Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, 61200, Brno, Czech Republic $1 https://orcid.org/0000000316406163
700    1_
$a Kostrhunova, Hana $u Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, 61200, Brno, Czech Republic $1 https://orcid.org/0000000327066491
700    1_
$a Kasparkova, Jana $u Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, 61200, Brno, Czech Republic $u Department of Biophysics, Palacky University, Slechtitelu 27, 783 71, Olomouc, Czech Republic $1 https://orcid.org/0000000252795381
700    1_
$a Gandin, Valentina $u Dipartimento di Scienze del Farmaco, Universita di Padova, 35131, Padova, Italy $1 https://orcid.org/0000000304420670
700    1_
$a Brabec, Viktor $u Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, 61200, Brno, Czech Republic $1 https://orcid.org/0000000282331393 $7 jo20010087133
700    1_
$a Gibson, Dan $u Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, 9112102, Israel $1 https://orcid.org/0000000216314018
773    0_
$w MED00000354 $t Angewandte Chemie. International edition in English $x 1521-3773 $g Roč. 62, č. 42 (2023), s. e202310774
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37646232 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093554 $b ABA008
999    __
$a ok $b bmc $g 2049576 $s 1210739
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 62 $c 42 $d e202310774 $e 20230912 $i 1521-3773 $m Angewandte Chemie. International edition in English $n Angew Chem Int Ed Engl $x MED00000354
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace